Maternal Serum Screening Markers and Adverse Outcome: A New PerspectiveReport as inadecuate




Maternal Serum Screening Markers and Adverse Outcome: A New Perspective - Download this document for free, or read online. Document in PDF available to download.

PerkinElmer Labs-NTD, 80 Ruland Road, Suite 1, Melville, NY 11747, USA



These authors contributed equally to this work.





*

Author to whom correspondence should be addressed.



Abstract There have been a number of studies evaluating the association of aneuploidy serum markers with adverse pregnancy outcome. More recently, the development of potential treatments for these adverse outcomes as well as the introduction of cell-free fetal DNA cffDNA screening for aneuploidy necessitates a re-evaluation of the benefit of serum markers in the identification of adverse outcomes. Analysis of the literature indicates that the serum markers tend to perform better in identifying pregnancies at risk for the more severe but less frequent form of individual pregnancy complications rather than the more frequent but milder forms of the condition. As a result, studies which evaluate the association of biomarkers with a broad definition of a given condition may underestimate the ability of such markers to identify pregnancies that are destined to develop the more severe form of the condition. Consideration of general population screening using cffDNA solely must be weighed against the fact that traditional screening using serum markers enables detection of severe pregnancy complications, not detectable with cffDNA, of which many may be amenable to treatment options. View Full-Text

Keywords: aneuploidy screening; preeclampsia; IUGR; preterm birth; fetal loss; placenta accreta; open neural tube defects aneuploidy screening; preeclampsia; IUGR; preterm birth; fetal loss; placenta accreta; open neural tube defects





Author: David Krantz * , Terrence Hallahan †, David Janik † and Jonathan Carmichael †

Source: http://mdpi.com/



DOWNLOAD PDF




Related documents